Validation of Seattle Heart Failure Model for mortality risk prediction in patients treated with cardiac resynchronization therapy

Survival prediction by the Seattle Heart Failure Model (SHFM) of patients treated with cardiac resynchronization therapy (CRT) remains ill defined. The performance of the SHFM in this clinical setting was therefore evaluated.

[1]  M. Emdin,et al.  Application of the Seattle Heart Failure Model in Patients on Cardiac Resynchronization Therapy , 2012, Pacing and clinical electrophysiology : PACE.

[2]  S. Solomon,et al.  Predictors of Response to Cardiac Resynchronization Therapy in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) , 2011, Circulation.

[3]  C. Sticherling,et al.  Characterization and financial impact of implantable cardioverter-defibrillator patients without interventions 5 years after implantation. , 2011, QJM : monthly journal of the Association of Physicians.

[4]  D. J. Veldhuisen,et al.  Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study , 2011, European journal of heart failure.

[5]  Jeroen J. Bax,et al.  Cardiac resynchronization therapy: a cost or an investment? , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[6]  L. Jordaens,et al.  The prognosis of implantable defibrillator patients treated with cardiac resynchronization therapy: comorbidity burden as predictor of mortality , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[7]  Finn Gustafsson,et al.  2010 Focused Update of ESC Guidelines on Device Therapy in Heart Failure , 2011 .

[8]  John L Sapp,et al.  Cardiac-resynchronization therapy for mild-to-moderate heart failure. , 2010, The New England journal of medicine.

[9]  Jeroen J. Bax,et al.  2010 Focused Update of ESC Guidelines on device therapy in heart failure , 2010, European journal of heart failure.

[10]  G. Biolo,et al.  Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". , 2010, Clinical nutrition.

[11]  Wojciech Zareba,et al.  Cardiac-resynchronization therapy for the prevention of heart-failure events. , 2009, The New England journal of medicine.

[12]  D. Mozaffarian,et al.  Maximizing Survival Benefit With Primary Prevention Implantable Cardioverter-Defibrillator Therapy in a Heart Failure Population , 2009, Circulation.

[13]  J. Butler,et al.  Utility of the Seattle Heart Failure Model in patients with advanced heart failure. , 2009, Journal of the American College of Cardiology.

[14]  A. Waldo.  Randomized Trial of Cardiac Resynchronization in Mildly Symptomatic Heart Failure Patients and in Asymptomatic Patients With Left Ventricular Dysfunction and Previous Heart Failure Symptoms , 2009 .

[15]  Stefano Ghio,et al.  Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. , 2008, Journal of the American College of Cardiology.

[16]  D. Mozaffarian,et al.  Prediction of Mode of Death in Heart Failure: The Seattle Heart Failure Model , 2007, Circulation.

[17]  Leslie Saxon,et al.  Effects of Cardiac Resynchronization Therapy With or Without a Defibrillator on Survival and Hospitalizations in Patients With New York Heart Association Class IV Heart Failure , 2006, Circulation.

[18]  Jeroen J. Bax,et al.  Postero‐Lateral Scar Tissue Resulting in Non‐Response to Cardiac Resynchronization Therapy , 2006, Journal of cardiovascular electrophysiology.

[19]  D. Mozaffarian,et al.  The Seattle Heart Failure Model: Prediction of Survival in Heart Failure , 2006, Circulation.

[20]  Jeroen J. Bax,et al.  Clinical versus echocardiographic parameters to assess response to cardiac resynchronization therapy. , 2006, The American journal of cardiology.

[21]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[22]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[23]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[24]  E. Foster,et al.  Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. , 2003, Journal of the American College of Cardiology.

[25]  R. Canby,et al.  Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. , 2003, JAMA.